62224-16-2

Usage

Uses

Used in Pharmaceutical Synthesis:
Methyl 4-bromothiophene-2-carboxylate is utilized as an intermediate in the synthesis of pharmaceuticals, contributing to the development of new drugs. Its role in this industry is pivotal due to its ability to serve as a versatile building block in organic synthesis, facilitating the creation of a wide range of medicinal compounds.
Used in Agrochemical Production:
In the agrochemical sector, Methyl 4-bromothiophene-2-carboxylate is employed in the production of crop protection products. Its application here is driven by its capacity to enhance the effectiveness of these products, thereby supporting agricultural productivity and crop health.
Used in Research Laboratories:
Methyl 4-bromothiophene-2-carboxylate also finds use in research laboratories as a reagent or substrate for various chemical reactions. Its unique structure and properties make it an indispensable tool for conducting experiments and advancing the understanding of organic chemical processes.

InChI:InChI=1/C6H5BrO2S/c1-9-6(8)5-2-4(7)3-10-5/h2-3H,1H3

Upstream product

• 67-56-1 methanol 
• 16694-18-1 4-bromo-thiophene-2-carboxylic acid 
• 58777-65-4 4-Bromothiophene-2-carboxylic acid chloride 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 872-31-1 3-Bromothiophene 
• 124-38-9 carbon dioxide 
• 74-88-4 methyl iodide 
• 77-78-1 dimethyl sulfate 
• 6324-10-3 4,5-Dibromo-thiophene-2-carboxylic acid 
• 18791-75-8 4-Bromothiophen-2-aldehyde 

Downstream Products

• 478374-81-1 methyl 4-(3-{[(t-butoxycarbonyl)-amino]methyl}-4-methoxyphenyl)-2-thiophenecarboxylate 
• 666721-41-1 methyl 4-(4-nitrophenyl)thiophene-2-carboxylate 
• 851340-17-5 4-(4-formyl-phenyl)-thiophene-2-carboxylic acid methyl ester 
• 31862-80-3 methyl 4-bromo-5-nitrothiophene-2-caboxylate 
• 709648-80-6 methyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-thiophene-2-carboxylate 
• 1204527-64-9 C₁₈H₁₅N₅O₂S 
• 1239576-63-6 methyl 4-[1-(phenylmethyl)-1H-pyrazol-4-yl]-2-thiophenecarboxylate 
• 1228581-03-0 methyl 5-bromo-4-phenyl-thiophene-2-carboxylate 
• 21676-90-4 methyl 4-phenylthiophene-2-carboxylate 
• 887911-68-4 3-(5-(4-cyclopropyl-2-imino-1-methyl-5-oxoimidazolidin-4-yl)thiophen-3-yl)benzonitrile 
• 721960-44-7 4-bromo-N-methoxy-N-methylthiophene-2-carboxamide 
• 848483-63-6 methyl 4-(4-chlorophenyl)-2-thiophenecarboxylate 
• 77133-27-8 4-methoxythiophene-2-carboxylic acid 
• 237384-71-3 Methyl 4-(4-phenyl-1,3-thiazol-2-yl)thiophene-2-carboxylate 

Relevant academic research and scientific papers

Discovery of 6-substituted thieno[2,3-d]pyrimidine analogs as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis in folate receptor

We discovered 6-substituted thieno[2,3-d]pyrimidine compounds (3–9) with 3–4 bridge carbons and side-chain thiophene or furan rings for dual targeting one-carbon (C1) metabolism in folate receptor- (FR) expressing cancers. Synthesis involved nine steps st

Ag(I)-Catalyzed C-H Carboxylation of Thiophene Derivatives

CO2utilization is an attractive aspect as it allows the direct conversion of CO2into valuable chemicals. In this regard, direct incorporation of CO2into the C-H bond of heteroaromatic compounds is important due to the ubiquitous structural motifs of the heteroaromatic carboxylic acids. Herein, we report the Ag-catalyzed C-H carboxylation of thiophene derivatives. This new catalytic system involving a phosphine ligand and lithiumtert-butoxide enables the direct carboxylation of thiophenes under mild reaction conditions. Experimental studies revealed that the use oftert-butyl alkoxide is critical for the exergonic formation of an arylsilver intermediate, and the results were further supported by density functional theory calculations.

Thiophene-Pyrazolourea Derivatives as Potent, Orally Bioavailable, and Isoform-Selective JNK3 Inhibitors

Potent JNK3 isoform selective inhibitors were developed from a thiophenyl-pyrazolourea scaffold. Through structure activity relationship (SAR) studies utilizing enzymatic and cell-based assays, and in vitro and in vivo drug metabolism and pharmacokinetic (DMPK) studies, potent and highly selective JNK3 inhibitors with oral bioavailability and brain penetrant capability were developed. Inhibitor 17 was a potent and isoform selective JNK3 inhibitor (IC50 = 35 nM), had significant inhibition to only JNK3 in a panel profiling of 374 wild-type kinases, had high potency in functional cell-based assays, had high stability in human liver microsome (t1/2 = 66 min) and a clean CYP-450 inhibition profile, and was orally bioavailable and brain penetrant. Moreover, cocrystal structures of compounds 17 and 27 in human JNK3 were solved at 1.84 ?, which showed that these JNK3 isoform selective inhibitors bound to the ATP pocket, had interactions in both hydrophobic pocket-I and hydrophobic pocket-II.

Combining structure- and property-based optimization to identify selective FLT3-ITD inhibitors with good antitumor efficacy in AML cell inoculated mouse xenograft model

FLT3 mutation is among the most common genetic mutations in acute myeloid leukemia (AML), which is also related with poor overall survival and refractory in AML patients. Recently, FLT3 inhibitors have been approved for AML therapy. Herein, a series of new compounds with pyrazole amine scaffold was discovered, which showed potent inhibitory activity against FLT3-ITD and significant selectivity against both FLT3-ITD and AML cells expressing FLT3-ITD. Compound 46, possessing the most promising cellular activity, blocked the autophosphorylation of FLT3 pathway in MV4-11 cell line. Furthermore, the apoptosis and downregulation of P-STAT5 were also observed in tumor cells extracted from the MV4-11 cell xenografts model upon compound 46 treatment. Compound 46 was also metabolically stable in vitro and suppressed tumor growth significantly in MV4-11 xenografts model in vivo. Compound 46 showed no toxicity to the viscera of mice and caused no decrease in body weight of mice. In conclusion, the results of this study could provide valuable insights into discovery of new FLT3 inhibitors, and compound 46 was worthy of further development as potential drug candidate to treat AML.

Substituted quinolinone inhibitor

The invention provides a substituted quinolinone inhibitor and relates to a compound as shown in a formula (II) which is described in the specification or a pharmaceutically acceptable salt, solvate,active metabolite, polymorphic substance, ester, isomer or prodrug thereof, a pharmaceutical composition containing the compound as shown in the formula (II), and application of the compound and the pharmaceutical composition to treatment of diseases related to abnormal TOPK activity.

2-thiazole cyclic substituted thiophen class PLK1 inhibitor and its use and its use

The invention relates to the field of medicinal chemistry, and in particular relates to 2-imidazole ring-substituted thiophene PLK1 (Polo-like kinase 1) inhibitors, a preparation method for the inhibitors, a medicinal composition containing the compounds, and medical applications for the compounds, and in particular an application for the compounds as Polo-like kinase 1 (PLK1) inhibitors.

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)-A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer's Disease

Verubecestat 3 (MK-8931), a diaryl amide-substituted 3-imino-1,2,4-thiadiazinane 1,1-dioxide derivative, is a high-affinity β-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor currently undergoing Phase 3 clinical evaluation for the treat

INHIBITORS OF AKT ACTIVITY

Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS

Compounds of formula (I) inhibit microtubule affinity regulating kinase (MARK), and hence are suitable for treating diseases associated with abnormal phosphorylation of tau.